| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ITOS | Common Stock | Options Exercise | $39.2K | +9.11K | +11.65% | $4.30 | 87.3K | Dec 20, 2021 | Direct | F1 |
| transaction | ITOS | Common Stock | Sale | -$400K | -9.11K | -10.44% | $43.94 | 78.2K | Dec 20, 2021 | Direct | F1, F2 |
| transaction | ITOS | Common Stock | Options Exercise | $82.7K | +19.2K | +24.59% | $4.30 | 97.4K | Dec 21, 2021 | Direct | F1 |
| transaction | ITOS | Common Stock | Sale | -$602K | -13.6K | -14.01% | $44.15 | 83.8K | Dec 21, 2021 | Direct | F1, F3 |
| transaction | ITOS | Common Stock | Sale | -$251K | -5.58K | -6.66% | $45.06 | 78.2K | Dec 21, 2021 | Direct | F1, F4 |
| transaction | ITOS | Common Stock | Options Exercise | $7.15K | +1.66K | +2.13% | $4.30 | 79.9K | Dec 22, 2021 | Direct | F1 |
| transaction | ITOS | Common Stock | Sale | -$67.1K | -1.51K | -1.9% | $44.31 | 78.3K | Dec 22, 2021 | Direct | F1, F5 |
| transaction | ITOS | Common Stock | Sale | -$6.69K | -149 | -0.19% | $44.92 | 78.2K | Dec 22, 2021 | Direct | F1 |
| transaction | ITOS | Common Stock | Sale | -$223K | -5.01K | -6.4% | $44.62 | 73.2K | Dec 22, 2021 | Direct | F1, F6 |
| transaction | ITOS | Common Stock | Sale | -$431K | -9.49K | -12.97% | $45.37 | 63.7K | Dec 22, 2021 | Direct | F1, F7 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ITOS | Stock Option (Right to Buy) | Gift | $0 | -313K | -77.69% | $0.00 | 90K | Dec 2, 2021 | Common Stock | 403K | $4.30 | Direct | F8, F9 |
| transaction | ITOS | Stock Option (Right to Buy) | Gift | $0 | +313K | $0.00 | 313K | Dec 2, 2021 | Common Stock | 313K | $4.30 | By MG3A | F8, F9 | |
| transaction | ITOS | Stock Option (Right to Buy) | Gift | $0 | -185K | -54.26% | $0.00 | 156K | Dec 2, 2021 | Common Stock | 341K | $4.23 | Direct | F8, F10 |
| transaction | ITOS | Stock Option (Right to Buy) | Gift | $0 | +185K | $0.00 | 185K | Dec 2, 2021 | Common Stock | 185K | $4.23 | By MG3A | F8, F10 | |
| transaction | ITOS | Stock Option (Right to Buy) | Gift | $0 | -52.7K | -75.02% | $0.00 | 17.5K | Dec 2, 2021 | Common Stock | 70.2K | $6.15 | Direct | F8, F11 |
| transaction | ITOS | Stock Option (Right to Buy) | Gift | $0 | +52.7K | $0.00 | 52.7K | Dec 2, 2021 | Common Stock | 52.7K | $6.15 | By MG3A | F8, F11 | |
| transaction | ITOS | Stock Option (Right to Buy) | Gift | $0 | -777K | -75% | $0.00 | 259K | Dec 2, 2021 | Common Stock | 1.04M | $19.00 | Direct | F8, F12 |
| transaction | ITOS | Stock Option (Right to Buy) | Gift | $0 | +777K | $0.00 | 777K | Dec 2, 2021 | Common Stock | 777K | $19.00 | By MG3A | F8, F12 | |
| transaction | ITOS | Stock Option (Right to Buy) | Gift | $0 | -106K | -73.75% | $0.00 | 37.8K | Dec 2, 2021 | Common Stock | 144K | $41.58 | Direct | F8, F13 |
| transaction | ITOS | Stock Option (Right to Buy) | Gift | $0 | +106K | $0.00 | 106K | Dec 2, 2021 | Common Stock | 106K | $41.58 | By MG3A | F8, F13 | |
| transaction | ITOS | Stock Option (Right to Buy) | Options Exercise | $0 | -9.11K | -10.12% | $0.00 | 80.9K | Dec 20, 2021 | Common Stock | 9.11K | $4.30 | Direct | F1, F9 |
| transaction | ITOS | Stock Option (Right to Buy) | Options Exercise | $0 | -19.2K | -23.77% | $0.00 | 61.7K | Dec 21, 2021 | Common Stock | 19.2K | $4.30 | Direct | F1, F9 |
| transaction | ITOS | Stock Option (Right to Buy) | Options Exercise | $0 | -1.66K | -2.7% | $0.00 | 60K | Dec 22, 2021 | Common Stock | 1.66K | $4.30 | Direct | F1, F9 |
| Id | Content |
|---|---|
| F1 | The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. |
| F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.8 to $44.2, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| F3 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.8 to $44.79, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| F4 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.825 to $45.29, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| F5 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.85 to $44.73, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| F6 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.12 to $45.11, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| F7 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.15 to $45.83, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| F8 | The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager. |
| F9 | One-fourth of the shares subject to the stock option vested on January 1, 2019. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date. |
| F10 | One-fourth of the shares subject to the stock option vested on May 1, 2021. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date. |
| F11 | One-fourth of the shares subject to the stock option vested on June 1, 2021. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date. |
| F12 | One-fourth of the shares subject to the stock option vested on July 23, 2021. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date. |
| F13 | One-fourth of the shares subject to the stock option will vest on March 1, 2022, subject to the reporting person's continuous service relationship with the Issuer. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date. |